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KDM4A regulates HIF-1 levels 
through H3K9me3
Grzegorz Dobrynin1, Tom E. McAllister  3, Katarzyna B. Leszczynska1, Shaliny 
Ramachandran1, Adam J. Krieg4, Akane Kawamura  2,3 & Ester M. Hammond1
Regions of hypoxia (low oxygen) occur in most solid tumours and cells in these areas are the most 
aggressive and therapy resistant. In response to decreased oxygen, extensive changes in gene 
expression mediated by Hypoxia-Inducible Factors (HIFs) contribute significantly to the aggressive 
hypoxic tumour phenotype. In addition to HIFs, multiple histone demethylases are altered in their 
expression and activity, providing a secondary mechanism to extend the hypoxic signalling response. In 
this study, we demonstrate that the levels of HIF-1α are directly controlled by the repressive chromatin 
mark, H3K9me3. In conditions where the histone demethylase KDM4A is depleted or inactive, 
H3K9me3 accumulates at the HIF-1α locus, leading to a decrease in HIF-1α mRNA and a reduction 
in HIF-1α stabilisation. Loss of KDM4A in hypoxic conditions leads to a decreased HIF-1α mediated 
transcriptional response and correlates with a reduction in the characteristics associated with tumour 
aggressiveness, including invasion, migration, and oxygen consumption. The contribution of KDM4A 
to the regulation of HIF-1α is most robust in conditions of mild hypoxia. This suggests that KDM4A 
can enhance the function of HIF-1α by increasing the total available protein to counteract any residual 
activity of prolyl hydroxylases.
Hypoxia occurs in most solid tumours as a consequence of the rapid proliferation of cancer cells and an inade-
quate/inefficient vasculature. Most importantly, the degree of tumour hypoxia has been shown to correlate with 
poor patient survival in numerous tumour types1. The predominant transcriptional response to hypoxia is medi-
ated by the hypoxia inducible factors (HIF), which include HIF-1, 2 and 32, 3. Each HIF is composed of the same 
constitutively expressed β subunit (HIF-1β) and an oxygen labile α subunit (HIF-1α, 2α or 3α). Under normoxic 
conditions, HIF-1α is hydroxylated by the prolyl hydroxylases (PHDs) within the N- and C- terminal oxygen 
dependent degradation domains (NODD and CODD)4. Once hydroxylated, HIF-1α interacts with the tumour 
suppressor, von-Hippel-Lindau complex (VHL), is ubiquitinated and targeted for proteosomal degradation. The 
PHDs are Fe(II) and 2-oxoglutarate (2-OG) dependent oxygenases and do not function in hypoxic conditions 
where insufficient oxygen is available, therefore allowing the stabilisation of HIF-α subunits and dimerisation 
with HIF-1β5. HIF-1α function is also regulated by another 2-OG oxygenase, factor inhibiting HIF (FIH). FIH 
hydroxylates an asparagine residue in the C-terminal transactivation domain of HIF1-α which prevents complex 
formation with p300, thus inhibiting transcriptional activation6. In addition to HIF-mediated changes in gene 
expression, the epigenetic landscape is also altered in response to hypoxia7, 8. KDM4A (JMJD2A) is a member of 
the histone lysine demethylase (KDM) family of enzymes that catalyse the removal of methyl groups from lysine 
residues and are involved in transcriptional regulation of gene expression9–11. Like the PHDs, the enzymatic 
activity of KDMs relies on 2-OG, Fe(II) and the presence of molecular oxygen as essential cofactors12–15. KDM4A 
expression has been reported to be increased in several cancer types including colorectal, this combined with a 
number of functional studies have suggested KDM4A is an attractive target for cancer therapy16–20. In this study, 
we describe a novel role for KDM4A in the regulation of HIF-1α mRNA expression and identify inhibition of 
KDM4A as a unique strategy to decrease HIF signalling. These findings strongly support the hypothesis that 
KDM4A is a potential therapeutic target for improving the treatment response of radioresistant, hypoxic solid 
tumours.
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Results
KDM4A as a therapeutic target. KDM4A has been described as over-expressed in a range of cancer types 
although the underlying mechanism is unclear. As both KDM4B and KDM4C have been demonstrated to be tar-
gets of HIF-1, we investigated the possibility that KDM4A is also hypoxia regulated by correlating expression with 
a previously described hypoxia signature21–23. Using the TCGA colorectal adenocarcinoma data set, we found no 
significant correlation between KDM4A expression and the hypoxia signature. In contrast, KDM4B expression 
did positively correlate with the hypoxia signature (Supplementary Figure S1A,B). In support of this finding there 
was no increase in KDM4A mRNA expression after exposure to hypoxia (2% or <0.1% O2) (Supplementary 
Figure S1C). However, in agreement with previous reports suggesting KDM4A has a pro-longed half-life in 
hypoxia, there was a clear increase in KDM4A protein levels in RKO cells exposed to either 2% or <0.1% O2, 
(Fig. 1A)24, 25. As expected, the levels of H3K9me3 and H3K36me3 increased in response to <0.1% O2 (Fig. 1B)26, 27. 
Interestingly, although the effect of depletion of KDM4A on the total levels of H3K9me3 and H3K36me3 was 
slight, this was most pronounced at 2% O2 (Fig. 1B and Supplementary Figure S1D). Since KDM4A has been 
described as having the potential to act as an oxygen sensor and is highly sensitive to oxygen concentration, it is 
likely that while KDM4A would retain activity in our mild hypoxic conditions (2% O2), it would be inactive at the 
more severe level (<0.1% O2)28. To evaluate KDM4A as a potential therapeutic target we examined the KDM4A-
dependent contribution to key biological processes associated with cancer aggressiveness. Depletion of KDM4A 
significantly decreased the extracellular acidification rate (ECAR) in RKO cells exposed to hypoxia, which is 
Figure 1. Biological consequences of siRNA-mediated KDM4A depletion. (A) RKO cells were exposed to 
the O2 concentrations indicated for the periods of time shown. N (normoxia) is 21% O2 for 24 h. Western 
blotting was carried out with the indicated antibodies. (B) RKO cells were transfected with siRNA to KDM4A 
(siKDM4A) or a non-targeting control siRNA and then incubated at 21%, 2% or <0.1% O2 for 24 h. Uncropped 
blots for the Fig. 1A and B are presented in Figure S5A and B. (C) ECAR was measured in RKO cells treated 
with siKDM4A or siCtrl. (D) RKO cells were treated with siKDM4A and then incubated in 2% O2 for 24 h 
and irradiated with 6 Gy while in hypoxic conditions (Supplementary Figure S1E)41. A colony survival assay is 
shown. (B) MDA-MB-231 cells were treated with siKDM4A or siCtrl and migration measured in 2% O2 over a 
period of 30 h. (F) MDA-MB-231 cells were treated with siKDM4A or siCtrl and invasion measured in 2% O2 
over a period of 40 h.
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representative of the glycolytic rate (Fig. 1C). Next, we asked if loss of KDM4A affected the radiosensitivity of 
cells in hypoxic conditions (2 and <0.1% O2). The radiosensitivity of RKO cells was unaffected by loss of KDM4A 
when cells were in normoxic or severely hypoxic (<0.1% O2) conditions, although as expected the cells in <0.1% 
O2 were significantly more radioresistant (Supplementary Figure S1E,F and G). However, there was a modest but 
significant increase in radiosensitivity when KDM4A was depleted from cells exposed to 2% O2 during radiation 
(Fig. 1D and Supplementary Figure S1G). We also examined the migration rate of the highly motile cell line, 
MDA-MB-231, depleted of KDM4A. As previously reported the migration rate of KDM4A-depleted cells in 21% 
O2 was lower, although in our hands this was not a significant decrease (Supplementary Figure S1I)29. However, in 
hypoxic conditions (2% O2) depletion of KDM4A led to a significant decrease in migration rate (Fig. 1E). Finally, 
depletion of KDM4A also led to a decreased invasion rate under hypoxic conditions (2% O2) (Fig. 1F). Together, 
these data support the hypothesis that KDM4A is a good candidate for therapeutic intervention and that this 
might be particularly effective as a means of targeting the radioresistant, hypoxic fraction of solid tumours.
Off-target effects of pharmacological KDM4A inhibitors can stabilise HIF-1α. To pursue a more 
clinically relevant method of KDM4A inhibition we employed the recently described inhibitor ML324, which is 
a small molecule displaying submicromolar inhibitory activity toward the JMJD2/KDM4 family30. As expected, 
when RKO cells were exposed to ML324 in either normoxic or hypoxic (2% O2) conditions the levels of H3K9me3 
increased significantly. Surprisingly, cells treated with ML324 in normoxic conditions had increased levels of 
HIF-1α (Fig. 2A and Supplementary Figure S2A,B). This finding was also observed in three oesophageal cancer 
cell lines (Supplementary Figure S2C). To determine whether this was due to a specific ML324 off-target effect, we 
used a second inhibitor, JIB-04, which inhibits the activity of the KDM family of histone demethylases, including 
KDM4A31. Again, HIF-1α levels were increased in response to the KDM4A inhibitor, and there was evidence that 
this led to a significant HIF-mediated response as the HIF-target Glut1 was also increased (Fig. 2B). We also used 
IOX1, a broad-spectrum, cell permeable inhibitor of most 2-OG oxygenases, including many members of the 
KDM demethylase family as well as PHD and FIH hydroxylases32. As expected, treatment of the RKO cells with 
IOX1 led to stabilisation of HIF-1α in normoxic conditions (Supplementary Figure S2D). In accordance with 
the normoxic stabilisation of HIF-1α in ML324-treated cells, we also observed a modest but significant increase 
in the HIF-1α target genes, Glut1 and VEGF in normoxia (Supplementary Figure S2E). This ML324-dependent 
increase in VEGF expression was also evident in hypoxic conditions (2% O2) (Supplementary Figure S2F). These 
data suggest that the HIF-1α stabilised in response to ML324 was active and sufficient to impact gene expression 
in both normoxia and hypoxia. This was further supported through the use of a luciferase reporter assay (Fig. 2C). 
Furthermore, treatment with ML324 increased cell motility in normoxia (Fig. 2D), decreased the oxygen con-
sumption rate (OCR) (Fig. 2E) and increased ECAR (Fig. 2F). Together these data demonstrate that ML324 does 
not mimic the biological consequences of depletion of KDM4A. In vitro characterisation of the inhibitory activity 
of ML324 against recombinant HIF hydroxylase enzymes PHD2 and FIH revealed that ML324 inhibits the HIF 
hydroxylases at micromolar range (Fig. 2G, Supplementary Figure S2G and H). Therefore, it is likely that ML324, 
like the broad-spectrum 2OG oxygenase inhibitor IOX1, also inhibits HIF hydroxylases in cells resulting in up 
regulation of HIF. Also, we cannot rule out other off-target effects in the cellular context. Interestingly, JIB-04 is 
a very weak inhibitor of PHD2 (IC50 > 100 μM) but shows HIF up regulation in cells. While inhibition of other 
PHD isoforms cannot be ruled out, HIF stabilisation by these inhibitors may also arise from indirect effect of cel-
lular PHD inhibition, via changes in iron availability as previously observed for metal-chelating 2OG oxygenase 
inhibitor scaffolds33. More KDM4 selective inhibitors are therefore needed in order to pharmacologically validate 
KDM4A as a therapeutic target34.
Depletion of KDM4A decreases the HIF-1 response in hypoxia. In contrast to ML324/JIB-04 treat-
ment, depletion of KDM4A using siRNA led to a significant decrease in HIF-1α levels in hypoxia. This decrease 
in HIF-1α was more significant in cells exposed to 2% O2 compared to <0.1% O2 following KDM4A depletion 
(Fig. 3A). The levels of CAIX and Glut1, both HIF-1 targets, were also decreased in a KDM4A-dependent man-
ner. Decreased HIF-1α after siRNA-mediated depletion of KDM4A was verified using 4 additional siRNAs to 
validate that this was not due to an off-target effect and was also verified in additional cell lines (MDA-MB-231 
and HCT116) (Supplementary Figure S3A,B and C). Interestingly, a decrease in HIF-2α was also observed in 
HCT116 cells exposed to hypoxia (2% O2) upon depletion of KDM4A (Supplementary Figure S3C). Decreased 
HIF-1 activity in hypoxia after KDM4A depletion was further confirmed using a reporter assay (Fig. 3B) and by 
measuring the expression of specific HIF target genes; Glut 1 (Supplementary Figure S3D), CAIX (Supplementary 
Figure S3E), SLC2A3/Glut3, which regulates metabolism (Fig. 3C) and TWIST1, which has a role in cell migra-
tion (Fig. 3D). In each case loss of KDM4A leads to decreased induction of the HIF-target gene in response to 
hypoxia (2% O2). Loss of KDM4A did not impact gene expression in <0.1% O2 and we attribute this to the oxygen 
dependency of KDM4A and suggest that as the demethylase would be unable to function at <0.1% O2, there was 
no added effect of reducing the level of KDM4A protein. To ensure that loss of KDM4A had not reduced tran-
scription in general we measured the expression of a non-hypoxia responsive gene, OAZ1, and found this to be 
unaffected by KDM4A loss (Supplementary Figure S3F). Interestingly, recent reports describe a novel mechanism 
in which KDM4A interacts with and co-activates the transcription factors E2F1 and ETV1, which have roles in 
regulating cell metabolism and migration20, 35. ZEB2 is a known target of E2F1 and HIF-1 and so we investigated 
the KDM4A-dependent effects on expression in both normoxia and hypoxia35. ZEB2 was not induced in response 
to hypoxia in the RKO cells used, however loss of KDM4A significantly decreased ZEB2 expression in both nor-
moxia and hypoxia (2% O2) (Fig. 3E). Loss of KDM4A had a similar effect on SNAI1 expression, which is regu-
lated by ETV1 and HIF-1 (Fig. 3F). It is likely that the KDM4A-dependent effects on ZEB2 and SNAI1 expression 
observed in normoxia could be attributed to decreased activity of E2F1 and ETV1 respectively, whilst the effects 
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seen in hypoxia may result from a combination of repressed E2F1/ETV1 and HIF-1 activity. Again, there was no 
significant impact of depleting KDM4A on gene expression in the more severe hypoxia (<0.1% O2).
HIF-1α mRNA expression is regulated by H3K9me3. HIF-1α stability is known to be controlled 
via post-translational modifications involving hydroxylation, acetylation, ubiquitination and phosphoryla-
tion36. To determine the mechanism behind the reduced levels of HIF-1α protein after KDM4A depletion, we 
Figure 2. ML324 stabilises HIF-1α protein levels in normoxic conditions (21% O2). (A) RKO cells were treated 
with ML324 (10 µM) for 48 h in either 21% or 2% O2. Western blotting was then carried out. (B) RKO cells 
were treated as in (A) with JIB-04 (5 µM). Uncropped blots are shown in Figure S6A and B. (C) RKO cells 
co-transfected with HRE (HIF-1 responsive element)-Firefly Luciferase and Renilla Luciferase were treated 
with ML324 (10 µM) for 24 h, incubated in 21% O2 or 2% O2 for an additional 24 h and the intensity of Firefly 
Luciferase was measured relative to the levels of Renilla Luciferase. (D) The relative motility of MCF-7 cells 
treated with ML324 was determined by xCELLigence assay. (E) Oxygen consumption rate (OCR) of RKO cells 
treated with ML324 (10 µM) for the indicated periods of time was measured. (F) Extracellular acidification rate 
(ECAR) of RKO cells treated with ML324 (10 µM) for the indicated periods of time was measured. (G) IC50 
determination of inhibitors against PHD2 and FIH using mass spectrometry assay. Italicised IC50 values are 
reported values from literature30–32. The recombinant proteins used were PHD2181-42643 and recombinant FIH as 
previously described44. Dose response curves were generated as shown in Supplementary Figure S2G and H and 
used to calculate the IC50 values shown.
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began by analysing the levels of HIF-1α mRNA in cells lacking KDM4A exposed to hypoxia (2 and <0.1% O2). 
Surprisingly, we found that loss of KDM4A led to a significant decrease in HIF-1α mRNA in both normoxia 
and the milder hypoxic conditions (2% O2) (Fig. 4A). A significant decrease in HIF-2αmRNA levels were also 
observed in cells depleted of KDM4A in hypoxic (2% O2) conditions (Supplementary Figure S4A). We did not 
see a similar effect on HIF-1α mRNA levels when KDM4B or C were depleted (Supplementary Figure S4B,C,D). 
These data also highlight that HIF-1α mRNA expression is reduced in severely hypoxic conditions (<0.1% O2) 
and that this was not further reduced by loss of KDM4A. A natural antisense of HIF-1α transcript (aHIF-1α), 
which is complementary to the 3′-untranslated region of the HIF-1α mRNA, has been described to serve as an 
additional level of HIF-1α transcription regulation37, 38. We asked whether KDM4A-depletion could influence the 
levels of aHIF-1α. We observed that the expression of aHIF-1α increased in response to hypoxia (2% and <0.1% 
O2), but depletion of KDM4A did not have significant effect (Fig. 4B). In addition, depletion of KDM4A did not 
have a significant effect on the levels of key transcription factors known to play a role in HIF-1α mRNA expres-
sion (Supplementary Figure S4E). As shown, depletion of KDM4A leads to an accumulation of both H3K9me3 
and H3K36me3, of these, H3K9me3 is associated with heterochromatin and gene repression (Fig. 1B)39. This led 
us to hypothesise that an accumulation of H3K9me3 at the HIF-1A gene could explain the loss of HIF-1α expres-
sion in response to loss of KDM4A. Using the UCSC genome browser (GRCh37/hg19 genome assembly), we 
found regions of moderate enrichment of the H3K9me3 chromatin mark along the HIF-1A gene (Supplementary 
Figure S4F). Therefore, we carried out a ChIP assay for H3K9me3 in KDM4A-depleted cells which were incu-
bated in normoxia or hypoxia (2 and <0.1% O2) (Fig. 4C). This analysis provided a number of key findings. 
Figure 3. Depletion of KDM4A leads to decrease of HIF-1α activity in hypoxia (2% O2). (A) RKO cells were 
treated with siKDM4A and then incubated in 21%, 2% or < 0.1% O2 for 24 h. Western blotting was carried 
out. Uncropped blots are shown in Figure S7. (B) FaDuHRE-Luc cells were treated as in part (A) and the relative 
intensity of Firefly Luciferase was measured relative to the number of cells in the respective conditions. RKO 
cells were treated as in part (A) and then mRNA levels were determined; (C) Glut3, (D) TWIST1, (E) ZEB2 and 
(F) SNAI1.
www.nature.com/scientificreports/
6SCIenTIfIC RepoRts | 7: 11094  | DOI:10.1038/s41598-017-11658-3
Firstly, we noticed that H3K9me3 accumulates at the HIF-1A gene in response to severe hypoxia (<0.1% O2), 
offering a potential explanation for why HIF-1α mRNA levels decrease in these conditions. Secondly, whilst 
H3K9me3 did not accumulate at the HIF-1α gene in response to 2% O2, this was significantly increased by the 
loss of KDM4A. Finally, loss of KDM4A did not alter the levels of H3K9me3 on the HIF-1A gene in severe 
hypoxia (<0.1% O2) and this is consistent with the demethylase being inactive in these conditions (Fig. 4D,E). 
In addition, we observed that depletion of KDM4A led to increased levels of H3K9me3 on the HIF-1A gene at 4 
other regions (Supplementary Figure S4G).
Discussion
This study describes a novel role of the KDM4A histone demethylase in regulating HIF-1α expression and activ-
ity. Most interestingly, our study describes a novel transcriptional method of HIF-1 regulation. In normal condi-
tions a balance of methyl transferase and demethylase activity regulates repressive marks such as H3K9me3 and 
Figure 4. Mechanism of KDM4A-dependent effect on HIF-1. RKO cells were treated with siKDM4A and then 
incubated in 21%, 2% or < 0.1% O2 for 24 h. qRT-PCR for HIF-1α (A) or aHIF-1α (B) is shown. (C) Cells were 
treated as in (A), then ChIP for H3K9me3 was performed and the enrichment of H3K9me3 on the HIF-1A gene 
relative to H3 in response to hypoxia were measured26. A schematic to demonstrate the regulation of HIF-1α by 
KDM4A. In normoxic or mildly hypoxic (2% O2) conditions the level of H3K9me3 associated with the HIF-1Α 
gene are low due to the activity of the methyl transferase and KDM4A (D). However, if KDM4A is depleted or 
inactivated due to lack of an essential co-factor (O2) or potentially a specific inhibitor, H3K9me3 accumulates 
leading to gene repression and decreased HIF-1α mRNA (E). In d and e the yellow hexagons represent 
H3K9me3.
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therefore gene expression. Here, we showed that when the activity of one such demethylase, KDM4A, is restricted 
due to depletion of the protein or lack of an essential co-factor, such as oxygen, H3K9me3 accumulates along the 
HIF-1A gene (Fig. 4E). This in turn leads to decreased levels of HIF-1α mRNA and reduced protein stabilisation/
activity.
Although inhibition of KDM4A has not undergone clinical testing yet in cancer patients it is widely considered 
an attractive strategy. Caution is warranted however, as the likely off-target effects of active-site metal-chelating 
KDM inhibitors include stabilising HIF through direct or indirect (e.g. via altering Fe(II) availability in cells) 
inhibition of related 2OG oxygenases PHD/FIH. Interestingly, a recent report demonstrated that LSD1 regulates 
HIF-1α, highlighting further overlap between the histone demethylases activity and HIF40. Most importantly, 
our data suggests that should specific KDM4A inhibitors become available they may well have the previously 
unforeseen benefit of reducing HIF activity and therefore significantly impact tumour aggressiveness and therapy 
resistance.
Methods
Cell lines, transfections and drug treatments. RKO, MCF7, MDA-MB-231, HCT116 and FaDuHRE-luc 
were cultured in Dulbecco’s modified Eagle’s medium (D-MEM) supplemented with 10% FBS and 1% penicillin/
streptomycin. For siRNA experiments, cells were transfected with 10 nM siRNA using Lipofectamine RNAiMAX 
in OptiMEM minimal medium (Invitrogen). As a negative control, ON-TARGETplus Non-targetting Control 
Pool siRNA (Dharmacon, D-001810-10) was used. siKDM4A S1 (Ambion, ID: 148456), siKDM4A Q1-Q4 
(Qiagen, 10274116), siKDM4B (Ambion, ID: 148507), siKDM4C (Ambion, ID: 108664), siKDM4D (Dharmacon, 
siGENOME SMARTpool D-020709-01 to 04). ML324 (Sigma-Aldrich, SML0741), JIB-04 (Sigma-Aldrich, 
SML0808) and IOX1 (Sigma Aldrich, SML0067).
Hypoxia treatment. Hypoxic treatments at 2% O2 were carried out in a Don Whitley H35 Hypoxystation 
and at <0.1% O2 in a Bactron chamber (Shel Lab). Radiation of cells in hypoxic conditions was carried out as 
previously described41. Values are presented as mean ± SEM of three independent experiments.
Immunoblotting. Cells were lysed in UTB (9 M urea, 75 mM Tris-HCl pH 7.5, 0.15 M β-mercaptoethanol) 
and briefly sonicated. Primary antibodies used: HIF-1a (BD Transduction Labs., 610959), KDM4A (Abcam, 
ab24545), CAIX (BioScience, AB1001), Glut1 (Abcam, ab14683), Actin (Santa Cruz, sc-69879), H3K9me3 
(Millipore, 07-422), H3K36me3 (Abcam, ab9050), H3 (Cell Signaling, 36385), NFκB p52 (Millipore, 05-361), 
Sp1 (Millipore, 07-645), E2F-1 (Cell Signaling, 3742S), HIF-2a (Novus Biologicals, NB100-122). Secondary anti-
bodies were IRDye® 680RD Goat anti-Mouse IgG (H+L), IRDye® 680RD Goat anti-Rabbit IgG (H+L), IRDye® 
800CW Donkey anti-Mouse IgG (H+L) and IRDye® 800CW Donkey anti-Rabbit IgG (H+L) from LI-COR 
Biosciences. Odyssey IR imaging technology (LI-COR Biosciences) was used for imaging.
qRT-PCR. mRNA was prepared using TRI reagent (Sigma). A NanoDrop was used for quantification. cDNA 
was synthesised using the Verso cDNA Enzyme kit (Life Technologies). qPCR was carried out with SYBR mix 
using a Step One Plus Real-time PCR Detection System (Applied Biosystems). All mRNA expression levels are 
normalised to siCtrl 18S mRNA. Primer sequences are available in the SI. Values are presented as mean ± SEM of 
three independent experiments.
HIF reporter assay. Luciferase was measured with Dual-Glo® Luciferase Assay System (Promega). Readings 
of RKO cells were normalised to Renila Luciferase signal whereas for FaDuHRE-Luc they were normalised to the 
number of cells in each condition. Values are presented as mean ± SEM of three independent experiments.
ChIP. As previously described27, IgG (Cell Signaling), H3 (Abcam, ab1791), H3K9me3 (Abcam, ab8898) anti-
bodies were used. Primers are listed in SI. Values are presented as mean ± SEM of three independent experiments.
Measurement of ECAR and OCR. ECAR was measured using a Seahorse Bioscience XF96 Extracellular 
Flux Analyzer (Agilent Technologies). RKO cells (16000 cells/well) were seeded on polystyrene Seahorse XF 
Cell Culture Microplates and depleted of KDM4A for 48 h. 24 h before the experiment, cells were incubated in 
2% O2 for 24 h. The medium was changed to physiological medium (XF Assay Medium with 5 mM Glucose, 5 
mM Pyruvate, 4 mM Glutamine, pH 7.4) and measurements immediately acquired. ECAR was calculated by the 
Seahorse XF96 software and subsequently normalised to cell number, which was quantified by staining the cells 
with Hoechst and measuring the intensity with POLARstar Omega microplate reader Spectrophotometer (BMG 
Labtech). Values are presented as mean ± SEM of three independent experiments.
xCELLigence assay. The xCELLigence Real-Time Cell Analyser (RTCA) DP Instrument equipped with 
a CIM-plate 16 (Roche) was used as previously42. For quantification, the cell index at indicated time points was 
averaged from three independent experiments.
Statistical analysis. Statistical significance was calculated using GraphPad Prism software. For qRT-PCR, 
HIF reporter assay, ChIP and Seahorse results unpaired, two-tailed t-test was used, whereas for xCELLigence and 
colony formation experiment Two-way ANOVA with Alpha 0.05 was employed.
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